ClinicalTrials.gg
RecruitingNCT07290036Updated Nov 6, 2026

A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults

A Phase 1 interventional study of Bimekizumab regimen 1 iv and Bimekizumab regimen 2 iv in Psoriatic Arthritis and Axial Spondyloarthritis, sponsored by UCB Biopharma SRL. Recruiting at 65 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Nov 6, 20262 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
392
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Arthritis, Psoriatic by UCB S.A. — 2 open to participants now, 3 under way, 1 of them phase 3. Arthritis, Psoriatic · UCB S.A..

Planned enrollment
8th of 17
392 · median 214
Started
2025
with 1 other
Phase 1
6 of 18
2 open now
Registered
18th of 18
by date

Among the 18 studies in Arthritis, Psoriatic by UCB S.A., this one is the 8th largest by planned enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2025, is one of 6 in phase 1, and was the 18th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

2 of the 18 studies in Arthritis, Psoriatic by UCB S.A. are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Arthritis, Psoriatic by UCB S.A., or all of them as a file.
02

Study summary

To demonstrate that bimekizumab administered intravenously is noninferior to subcutaneous administration.

03

Conditions studied

  • Psoriatic Arthritis
  • Axial Spondyloarthritis

Keywords

  • Bimekizumab, BKZ, Phase 1B
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be 18+ years old and legally able to consent
  2. Have active psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA), suitable for bimekizumab treatment
  3. Weigh between 45-100 kg (females) or 50-100 kg (males).
  4. Be biologic disease-modifying anti-rheumatic drug (bDMARD)-naïve or have stopped bDMARDs ≥3 months or 5 half-lives ago

Exclusion criteria

Exclusion Criteria:

  1. Serious organ system disorders (e.g., heart, liver, kidney, gastrointestinal, neuro)
  2. Severe psychiatric issues or substance abuse in the past year
  3. Recent or chronic infections, including tuberculosis (TB) or nontuberculous mycobacterium (NTMB)
  4. Other inflammatory diseases (e.g., rheumatoid arthritis (RA), lupus, inflammatory bowel disease (IBD))
  5. Recent (within 8 weeks) or Bacillus Calmette-Guerin (BCG) (within 1 year)
  6. Recent use of glucagon-like peptide-1 (GLP-1) agonists (within 28 weeks)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
392 participants (estimated)

Study arms

  • Experimental
    Bimekizumab arm 1

    Subjects participating in the study will receive assigned bimekizumab dosing regimen 1 or 2 during the PK Lead-In Phase and dosing regimen 1 or 2 during Treatment Period.

    Drug: Bimekizumab regimen 1 iv · Drug: Bimekizumab regimen 2 iv

  • Experimental
    Bimekizumab arm 2

    Subjects participating in the study will receive assigned bimekizumab dosing regimen 3 during the PK Lead-In Phase and dosing regimen 3 during Treatment Period.

    Drug: Bimekizumab regimen 3 sc

Interventions

  • DrugBimekizumab regimen 1 iv

    Participants will receive bimekizumab (BKZ) at pre-specified time points.

  • DrugBimekizumab regimen 2 iv

    Participants will receive bimekizumab (BKZ) at pre-specified time points.

  • DrugBimekizumab regimen 3 sc

    Participants will receive bimekizumab (BKZ) at pre-specified time points.

06

What researchers measure

Primary outcomes

  1. Steady-state Trough Concentration (Ctrough,ss) at Week 16

    Steady-state trough concentration (Ctrough,ss) will be reported.

    Time frame: Week 16

Secondary outcomes

  1. Occurrence of treatment-emergent Adverse Events (TEAEs) from Baseline to the end of Safety Follow-Up (SFU) Visit

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. A TEAE is defined as any AE with a start on or after the first administration of study intervention and on or before 17 weeks after the final administration of study intervention. This includes AEs that worsen in intensity after the start of study intervention.

    Time frame: From Baseline to the end of SFU Visit (up to Week 29)

  2. Occurrence of treatment-emergent Serious Adverse Events (SAEs) from Baseline to the end of SFU Visit

    An SAE is any untoward medical occurrence that, at any dose, meets 1 or more of the criteria listed: Results in death; Is life-threatening; Requires inpatient hospitalization or prolongation of existing hospitalization; Results in persistent or significant disability/incapacity; Is a congenital anomaly/birth defect; Other situations: Important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention. A TEAE is defined as any AE with a start on or after the first administration of study intervention and on or before 17 weeks after the final administration of study intervention. This includes AEs that worsen in intensity after the start of study intervention.

    Time frame: From Baseline to the end of SFU Visit (up to Week 29)

  3. Occurrence of TEAEs leading to withdrawal of study intervention

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. A TEAE is defined as any AE with a start on or after the first administration of study intervention and on or before 17 weeks after the final administration of study intervention. This includes AEs that worsen in intensity after the start of study intervention. TEAEs leading to withdrawal of IMP of the study will be reported.

    Time frame: From Baseline to the end of SFU Visit (up to Week 29)

07

Study locations

65 of 65 sites recruiting
  • Pa0019 114
    Peoria, Arizona 85381-5025, United States
    Recruiting
  • Pa0019 127
    Apple Valley, California 92307, United States
    Recruiting
  • Pa0019 111
    Covina, California 91722, United States
    Recruiting
  • Pa0019 119
    Fullerton, California 92835, United States
    Recruiting
  • Pa0019 117
    Riverside, California 92518, United States
    Recruiting
  • Pa0019 125
    San Leandro, California 94578, United States
    Recruiting
  • Pa0019 126
    Temecula, California 92592, United States
    Recruiting
  • Pa0019 141
    Upland, California 91786, United States
    Recruiting
  • Pa0019 120
    Whittier, California 90602, United States
    Recruiting
  • Pa0019 128
    Whittier, California 90602, United States
    Recruiting
  • Pa0019 123
    Fort Collins, Colorado 80528, United States
    Recruiting
  • Pa0019 143
    Ormond Beach, Florida 32174, United States
    Recruiting
  • Pa0019 113
    South Miami, Florida 33155, United States
    Recruiting
  • Pa0019 133
    Zephyrhills, Florida 33542, United States
    Recruiting
  • Pa0019 132
    Chicago, Illinois 60661, United States
    Recruiting
  • Pa0019 134
    Lansing, Michigan 48911, United States
    Recruiting
  • Pa0019 140
    West Long Branch, New Jersey 07764-1503, United States
    Recruiting
  • Pa0019 131
    Albuquerque, New Mexico 87102, United States
    Recruiting
  • Pa0019 144
    Vandalia, Ohio 45377, United States
    Recruiting
  • Pa0019 115
    Duncansville, Pennsylvania 16635, United States
    Recruiting
  • Pa0019 142
    Rock Hill, South Carolina 29732, United States
    Recruiting
  • Pa0019 116
    Jackson, Tennessee 38305, United States
    Recruiting
  • Pa0019 138
    Murfreesboro, Tennessee 37128, United States
    Recruiting
  • Pa0019 129
    Baytown, Texas 77521, United States
    Recruiting
  • Pa0019 136
    Colleyville, Texas 76034, United States
    Recruiting
  • Pa0019 135
    Mesquite, Texas 75150, United States
    Recruiting
  • Pa0019 124
    Plano, Texas 75075, United States
    Recruiting
  • Pa0019 121
    Bellevue, Washington 98004, United States
    Recruiting
  • Pa0019 145
    Spokane, Washington 99216, United States
    Recruiting
  • Pa0019 130
    Beckley, West Virginia 25801, United States
    Recruiting
  • Pa0019 204
    Lovech, Bulgaria
    Recruiting
  • Pa0019 205
    Pleven, Bulgaria
    Recruiting
  • Pa0019 201
    Plovdiv, Bulgaria
    Recruiting
  • Pa0019 202
    Plovdiv, Bulgaria
    Recruiting
  • Pa0019 203
    Plovdiv, Bulgaria
    Recruiting
  • Pa0019 705
    Brno, Czechia
    Recruiting
  • Pa0019 703
    Hlučín, Czechia
    Recruiting
  • Pa0019 704
    Ostrava, Czechia
    Recruiting
  • Pa0019 702
    Uherské Hradiště, Czechia
    Recruiting
  • Pa0019 305
    Berlin, Germany
    Recruiting
  • Pa0019 301
    Hamburg, Germany
    Recruiting
  • Pa0019 302
    Ratingen, Germany
    Recruiting
  • Pa0019 306
    Wetzlar, Germany
    Recruiting
  • Pa0019 407
    Bialystok, Poland
    Recruiting
  • Pa0019 418
    Bialystok, Poland
    Recruiting
  • Pa0019 419
    Bydgoszcz, Poland
    Recruiting
  • Pa0019 404
    Bytom, Poland
    Recruiting
  • Pa0019 401
    Elblag, Poland
    Recruiting
  • Pa0019 412
    Krakow, Poland
    Recruiting
  • Pa0019 402
    Lodz, Poland
    Recruiting
  • Pa0019 410
    Lublin, Poland
    Recruiting
  • Pa0019 413
    Nowa Sól, Poland
    Recruiting
  • Pa0019 417
    Olsztyn, Poland
    Recruiting
  • Pa0019 406
    Poznan, Poland
    Recruiting
  • Pa0019 408
    Poznan, Poland
    Recruiting
  • Pa0019 411
    Poznan, Poland
    Recruiting
  • Pa0019 415
    Płońsk, Poland
    Recruiting
  • Pa0019 416
    Torun, Poland
    Recruiting
  • Pa0019 405
    Warsaw, Poland
    Recruiting
  • Pa0019 409
    Warsaw, Poland
    Recruiting
  • Pa0019 414
    Warsaw, Poland
    Recruiting
  • Pa0019 420
    Wroclaw, Poland
    Recruiting
  • Pa0019 601
    Košice, Slovakia
    Recruiting
  • Pa0019 602
    Košice, Slovakia
    Recruiting
  • Pa0019 603
    Piešťany, Slovakia
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — The sponsor does not plan to share IPD.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for May 2028, 29 months after the start.

Of 15 phase 1 interventional studies under Arthritis, Psoriatic, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 35. This study's planned 29 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2025
First posted
Dec 17, 2025
StartActual
Dec 10, 2025
Primary completionEst.
May 18, 2028
CompletionEst.
Sep 14, 2028
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (1 Poland, 1 Slovakia)
  • Pa0019 419 · Bydgoszcz, Poland
  • Pa0019 602 · Košice, Slovakia
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    2 sites added
    Show 2 added (1 Poland, 1 Slovakia)
    • Pa0019 419 · Bydgoszcz, Poland
    • Pa0019 602 · Košice, Slovakia
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07290036
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Dec 17, 2025
Start date
Dec 10, 2025
Primary completion
May 18, 2028 (estimated)
Completion
Sep 14, 2028 (estimated)
Last update
Nov 6, 2026

Study contacts

UCB Cares
Contact
ucbcares@ucb.com
+18445992273
UCB Cares
Contact
+18445992273
UCB Cares
study director · 001 844 599 22733 (UCB)

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion